Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 02 2021
25 02 2021
Historique:
received:
27
09
2020
accepted:
08
02
2021
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Fibroblast growth factor receptor 2 (FGFR2) has two isoforms: IIIb type and IIIc type. Clinicopathologic significance of these two FGFR2 subtypes in gastric cancer remains to be known. This study aimed to clarify the clinicopathologic difference of FGFR2IIIb and/or FGFR2IIIc overexpression. A total of 562 patients who underwent gastrectomy was enrolled. The expressions of FGFR2IIIb and FGFR2IIIc were retrospectively examined by immunohistochemistry or fluorescence in situ hybridization (FISH) using the 562 gastric tumors. We evaluated the correlation between clinicopathologic features and FGFR2IIIb overexpression and/or FGFR2IIIc overexpression in gastric cancer. FGFR2IIIb overexpression was observed in 28 cases (4.9%), and FGFR2IIIc overexpression was observed in four cases (0.7%). All four FGFR2IIIc cases were also positive for FGFR2IIIb, but not in the same cancer cells. FGFR2IIIb and/or FGFR2IIIc overexpression was significantly correlated with lymph node metastasis and clinical stage. Both FGFR2IIIb and FGFR2IIIc were significantly associated with poor overall survival. A multivariate analysis showed that FGFR2IIIc expression was significantly correlated with overall survival. FISH analysis indicated that FGFR2 amplification was correlated with FGFR2IIIb and/or FGFR2IIIc overexpression. These findings suggested that gastric tumor overexpressed FGFR2IIIc and/or FGFR2IIIb at the frequency of 4.9%. FGFR2IIIc overexpression might be independent prognostic factor for patients with gastric cancer.
Identifiants
pubmed: 33633310
doi: 10.1038/s41598-021-84107-x
pii: 10.1038/s41598-021-84107-x
pmc: PMC7907198
doi:
Substances chimiques
FGFR2 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4698Références
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Cancer Res. 2003 Dec 15;63(24):8848-52
pubmed: 14695201
Cancer Lett. 2011 Aug 1;307(1):47-52
pubmed: 21482024
Int J Oncol. 2006 Feb;28(2):307-14
pubmed: 16391783
Cells. 2019 Jun 25;8(6):
pubmed: 31242658
Br J Cancer. 2012 Feb 14;106(4):727-32
pubmed: 22240789
Carcinogenesis. 2013 Oct;34(10):2198-205
pubmed: 23880303
Cancer Res. 2006 Dec 1;66(23):11271-8
pubmed: 17145872
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1069-76
pubmed: 24696723
Genome Med. 2017 Oct 31;9(1):93
pubmed: 29089060
World J Gastrointest Oncol. 2020 Jan 15;12(1):1-20
pubmed: 31966910
J Transl Med. 2019 Jun 4;17(1):189
pubmed: 31164161
Cancer Res. 2008 Apr 1;68(7):2340-8
pubmed: 18381441
J Cell Physiol. 2014 Dec;229(12):1887-95
pubmed: 24733629
Clin Cancer Res. 1996 Aug;2(8):1373-81
pubmed: 9816310
Am J Pathol. 2012 May;180(5):1928-41
pubmed: 22440254
Mol Med Rep. 2013 May;7(5):1381-6
pubmed: 23545898
Mol Cancer Ther. 2012 Sep;11(9):2010-20
pubmed: 22778155
Oncotarget. 2017 May 30;8(22):36484-36491
pubmed: 28445128
Lab Invest. 1998 Sep;78(9):1143-53
pubmed: 9759658
J Clin Oncol. 2020 Jul 20;38(21):2418-2426
pubmed: 32167861
Hum Pathol. 2012 Oct;43(10):1559-66
pubmed: 22440694
Med Res Rev. 2014 Mar;34(2):280-300
pubmed: 23696246
Carcinogenesis. 2015 Dec;36(12):1511-20
pubmed: 26385890
Future Oncol. 2019 Jun;15(18):2073-2082
pubmed: 31094225
Clin Cancer Res. 2010 Dec 1;16(23):5750-8
pubmed: 20670946
Br J Cancer. 2014 Feb 18;110(4):967-75
pubmed: 24457912
Ann Surg Oncol. 2019 Apr;26(4):1093-1102
pubmed: 30652228
Oncogene. 2014 Sep 4;33(36):4485-95
pubmed: 24077287
Cell Mol Gastroenterol Hepatol. 2017 Jan 14;3(2):211-217
pubmed: 28275688
J Oncol Pharm Pract. 2020 Dec 29;:1078155220983425
pubmed: 33375902
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cancer Sci. 2020 Dec;111(12):4500-4509
pubmed: 32946655
Br J Cancer. 2020 Dec 3;:
pubmed: 33268819
Hum Cell. 2018 Oct;31(4):271-281
pubmed: 29876827
Oncogene. 1997 Dec 18;15(25):3059-65
pubmed: 9444954
J Transl Med. 2011 Jul 25;9:119
pubmed: 21781349
World J Gastroenterol. 2018 Jul 14;24(26):2818-2832
pubmed: 30018477
Gut. 2012 May;61(5):673-84
pubmed: 22315472
World J Gastroenterol. 2014 Dec 28;20(48):18306-15
pubmed: 25561797
Cancer Genet Cytogenet. 1993 Feb;65(2):111-4
pubmed: 8453595
J Nucleic Acids. 2012;2012:950508
pubmed: 22203889
Int J Cancer. 2010 Feb 15;126(4):1004-16
pubmed: 19621385
Ann Oncol. 2014 Mar;25(3):552-563
pubmed: 24265351
Genome Biol. 2014 Aug 27;15(8):428
pubmed: 25315765
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5983-7
pubmed: 2377625
World J Gastroenterol. 2016 Feb 28;22(8):2415-23
pubmed: 26937130
Mol Clin Oncol. 2014 Jul;2(4):509-517
pubmed: 24940486
Gastroenterology. 2006 Nov;131(5):1530-41
pubmed: 17101326
HPB (Oxford). 2014 Mar;16(3):204-11
pubmed: 23782313
Front Biosci (Landmark Ed). 2018 Jan 1;23:626-639
pubmed: 28930565
Oncol Rep. 2009 Apr;21(4):875-80
pubmed: 19287982
Br J Cancer. 2014 Mar 4;110(5):1169-78
pubmed: 24518603
Pharmacol Ther. 2010 Jan;125(1):105-17
pubmed: 19874848
Cancers (Basel). 2019 Dec 25;12(1):
pubmed: 31881796
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Dev Biol. 1993 Aug;158(2):475-86
pubmed: 8393815
Clin Cancer Res. 2013 May 1;19(9):2572-83
pubmed: 23493349